Search

Your search keyword '"Degasperi, E"' showing total 303 results

Search Constraints

Start Over You searched for: Author "Degasperi, E" Remove constraint Author: "Degasperi, E"
303 results on '"Degasperi, E"'

Search Results

2. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

3. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study

4. Survey on hepatic sarcoidosis in Italy

5. RESIST Criteria: A biochemical algorithm to reduce the number of unnecessary upper endoscopies for the evaluation of portal hypertension in compensated HBV-cirrhotic patients

6. Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di)

7. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study

8. Improvement of clinical parameters in HDV patients with advanced compensated cirrhosis treated with Bulevirtide monotherapy for 48 weeks

9. OC.12.2 RESIST CRITERIA: A BIOCHEMICAL ALGORITHM TO REDUCE THE NUMBER OF UNNECESSARY UPPER ENDOSCOPIES FOR THE EVALUATION OF PORTAL HYPERTENSION IN COMPENSATED HBVCIRRHOTIC PATIENTS

10. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS)

11. Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.

12. Hepatitis delta virus (hdv) replication through hbv integrants in hcc recurrence after liver transplantation.

13. Development and validation of an artificial intelligence PIVKA-II-based model for the prediction of hepatocellular carcinoma development in patients with HCV-related cirrhosis successfully treated with direct-acting antivirals

14. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

15. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

16. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives

17. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

18. Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis

19. Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort

20. Switching tdf treated patients to taf is a safe and effective strategy even in difficult-to-manage elderly patients with hbv-related cirrhosis and significant comorbidities: a real-life prospective study

21. Divergent patterns of hbv-rna and hbcrag levels in untreated chronic hepatitis delta: a large european cross-sectional study

25. Effectiveness and safety of bulevirtide monotherapy 2 mg/die in hdv patients with compensated cirrhosis and clinically significant portal hypertension

26. Humoral, cellular, clinical responses and safety of two doses of SARS-CoV-2 Messenger RNA vaccine in patients with compensated and decompensated cirrhosis: a long-term single center prospective study

27. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

28. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

29. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure

30. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

31. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

32. Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach

33. The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD)

40. A genetic risk score predicts de novo hepatocellular carcinoma in hepatits c cirrhotic patients treated with direct-acting antivirals

41. The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated HCV virus infection: An interim analysis in the PITER cohort

42. PIVKA_II a useful biomarker for hepatocellular carcinoma in caucasian HCV cirrhotic patients treated with direct-acting antivirals

43. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

44. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

45. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

47. From current status to optimization of HCV treatment: Recommendations from an expert panel

48. L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV

49. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Catalog

Books, media, physical & digital resources